{"id":"W2803642760","doi":"10.1016/j.jtho.2018.05.015","title":"Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; Celgene; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Erlotinib; Nivolumab; Oncology; Mutant; Internal medicine; Epidermal growth factor receptor; Cancer; Immunotherapy; Genetics; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004953974,0.0004181375,0.001556023,0.0002077951,0.0003899232,0.000707845,0.0003298715,0.0005751722,0.0009413348],"category_scores_gemma":[0.0009250526,0.0001987564,0.001164078,0.0002739752,0.0002061308,0.0007733831,0.0002236734,0.001215373,0.0002267781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008459464,"about_ca_system_score_gemma":0.001014702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001729486,"about_ca_topic_score_gemma":0.006794268,"domain_scores_codex":[0.9997341,0.00007311872,0.00003354212,0.00004677675,0.0000328027,0.00007966987],"domain_scores_gemma":[0.9997495,0.00007048753,0.00003506991,0.0000122126,0.00002659681,0.0001062533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3071704,0.003814141,0.2256638,0.001667942,0.003882088,0.002867496,0.0003489166,0.005737544,0.01769249,0.0004731113,0.006899302,0.4237828],"study_design_scores_gemma":[0.04812345,0.1300998,0.7407628,0.0008985545,0.01217023,0.008134926,0.001162963,0.01353499,0.00821079,0.002077278,0.03457947,0.0002447462],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863837,0.01007714,0.0001378554,0.0006713775,0.0002992638,0.00006906844,0.0001960394,0.00002553939,0.002139916],"genre_scores_gemma":[0.9969657,0.001660499,0.0001582955,0.0003164505,0.0001161063,0.00002822794,0.0002631247,0.00000429794,0.0004872894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001729486,"threshold_uncertainty_score":0.006137848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01299852903325221,"score_gpt":0.3669118231277166,"score_spread":0.3539132940944644,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}